Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 11/20 | 0.63 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.57 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.54 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.48 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.48 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7966084 | 0.84 | ADRA1D (0.66) | DRD2SIGMAR1ADRA1AADRA1DADRA1B | |
| SCHEMBL6198575 | 0.81 | DRD2 (0.55) | DRD2SIGMAR1ADRA1AADRA1DADRA1B | |
| SCHEMBL7524346 | 0.81 | ADRA1A (0.57) | DRD2SIGMAR1ADRA1AADRA1DADRA1B | |
| SCHEMBL6197779 | 0.81 | DRD2 (0.55) | DRD2SIGMAR1ADRA1AADRA1DADRA1B | |
| SCHEMBL19734921 | 0.81 | SIGMAR1 (0.68) | DRD2SIGMAR1 | |
| SCHEMBL12501782 | 0.81 | DRD2 (0.65) | DRD2SIGMAR1 | |
| Biphenyl SCHEMBL28784863 | 0.81 | DRD2 (0.62) | DRD2SIGMAR1CNR2 | |
| SCHEMBL7677837 | 0.81 | DRD2 (0.59) | DRD2SIGMAR1ADRA1ACNR2 | |
| SCHEMBL8254760 | 0.79 | DRD2 (0.64) | DRD2SIGMAR1 | |
| SCHEMBL8611359 | 0.79 | DRD2 (0.50) | DRD2SIGMAR1ADRA1ACNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020010186-A1 | Dihydropyrimidines and uses thereof | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-01-24 | — | — | US | disclosed |
| US-6245773-B1 | BENIGN PROSTATIC HYPERPLAMIA; REDUCTION OF INTRAOCULAR PRESSURE | SYNAPTIC PHARMACEUTICAL CORPORATION | 2001-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010186-A1 | Dihydropyrimidines and uses thereof | QDPR, DPYD, ADRA1D | DRD2 1498/4885SIGMAR1 534/4885ADRA1A 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.